Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich

BMC Infectious Diseases

Roberto F Speck³  Reinhard Zbinden¹  Christian Ruef⁶  Alexander Schweiger²  Silke Peter⁴  Bruno Ledergerber³  Simon Stelling⁵  Silvana K Rampini⁷  Andrea C Büchler³ 

[1] Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30/32, Zurich, 8006, Switzerland;Current address: Internal Medicine, Hospital Schwyz, Waldeggstrasse 10, Schwyz, 6430, Switzerland;Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland;Current address: Institute of Medical Microbiology and Hygiene, University of Tübingen, Elfriede-Aulhorn Str. 6, Tübingen, Germany;Current address: Ergon Informatik AG, Kleinstrasse 15, Zürich, 8008, Switzerland;Current address: Hirslanden Klinik, Witellikerstrasse 40, Zürich, 8032, Switzerland;Division of Internal Medicine, University Hospital of Zurich, University of Zurich, Raemistrasse 100, Zurich, 8091, Switzerland

关键词: EUCAST;    Diarrhea;    Antibiotic susceptibility;    Clostridium difficile;   

Others  :  1121945
DOI  :  10.1186/s12879-014-0607-z

 received in 2014-01-15, accepted in 2014-11-03,  发布年份 2014

【 摘 要 】

Background

Clostridium difficile infection (CDI) remains a major health problem worldwide. Antibiotic use, in general, and clindamycin and ciprofloxacin, in particular, have been implicated in the pathogenesis of CDI. Here, we hypothesized that antibiotics that are highly active in vitro against C. difficile are less frequently associated with CDI than others. The primary goals of our study were to determine if antibiotic susceptibility and CDI are associated and whether the antimicrobial susceptibility of C. difficile changed over the years.

Methods and results

We examined a large panel of C. difficile strains collected in 2006–2008 at the University Hospital of Zurich. We found that the antimicrobial susceptibilities to amoxicillin/clavulanate, piperacillin/tazobactam, meropenem, clindamycin, ciprofloxacin, ceftriaxone, metronidazole and vancomycin were similar to those reported in the literature and that they are similar to those reported in other populations over the last two decades. Antibiotic activity did not prevent CDI. For example, thre use of meropenem, which is highly active against all strains tested, was a clear risk factor for CDI. Most of the antibiotics tested also showed a higher minimum inhibitory concentration distribution than that of EUCAST. All strains were susceptible to metronidazole. One strain was resistant to vancomycin.

Conclusions

Antibiotic susceptibilities of the collection of C. difficile from the University Hospital of Zurich are similar to those reported by others since the 1980. Patients treated with carbapenems and cephalosporins had the highest risk of developing CDI irrespective of the antimicrobial activity of carbapenems.

【 授权许可】

   
2014 Büchler et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB: Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978, 298(10):531-534.
• [2]Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM: Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case–control study. BMC Infect Dis 2011, 11:194. BioMed Central Full Text
• [3]Taylor NS, Thorne GM, Bartlett JG: Comparison of two toxins produced by Clostridium difficile. Infect Immun 1981, 34(3):1036-1043.
• [4]Sullivan NM, Pellett S, Wilkins TD: Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun 1982, 35(3):1032-1040.
• [5]Noren T: Clostridium difficile and the disease it causes. Methods Mol Biol 2010, 646:9-35.
• [6]Karas JA, Enoch DA, Aliyu SH: A review of mortality due to Clostridium difficile infection. J Infect 2010, 61(1):1-8.
• [7]Tschudin-Sutter S, Widmer AF, Perl TM: Clostridium difficile: novel insights on an incessantly challenging disease. Curr Opin Infect Dis 2012, 25(4):405-411.
• [8]Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
• [9]Shen A: Clostridium difficile toxins: mediators of inflammation. J Innate Immun 2012, 4(2):149-158.
• [10]McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353(23):2433-2441.
• [11]Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353(23):2442-2449.
• [12]Gerding DN: Clostridium difficile 30 years on: what has, or has not, changed and why? Int J Antimicrob Agents 2009, 33(Suppl 1):S2-S8.
• [13]Baxter R, Ray GT, Fireman BH: Case–control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008, 29(1):44-50.
• [14]Bignardi GE: Risk factors for Clostridium difficile infection. J Hosp Infect 1998, 40(1):1-15.
• [15]Phillips ST, Nagaro K, Sambol SP, Johnson S, Gerding DN: Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. Anaerobe 2011, 17(4):166-169.
• [16]Chang TW, Lauermann M, Bartlett JG: Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis 1979, 140(5):765-770.
• [17]Spigaglia P, Mastrantonio P: Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002, 40(9):3470-3475.
• [18]Citron DM, Ostovari MI, Karlsson A, Goldstein EJ: Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol 1991, 29(10):2197-2203.
• [19]Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN: Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107(7):1001-1010.
• [20]Chow AW, Cheng N, Bartlett KH: In vitro susceptibility of Clostridium difficile to new beta-lactam and quinolone antibiotics. Antimicrob Agents Chemother 1985, 28(6):842-844.
• [21]Delmee M, Avesani V: Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 1986, 29(2):374-375.
• [22]Clabots CR, Peterson LR, Gerding DN: Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing. J Infect Dis 1988, 158(4):731-736.
• [23]Cheng SH, Chu FY, Lo SH, Lu JJ: Antimicrobial susceptibility of Clostridium difficile by E test. J Microbiol Immunol Infect 1999, 32(2):116-120.
• [24]Dzink J, Bartlett JG: In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother 1980, 17(4):695-698.
• [25]Nakamura S, Nakashio S, Mikawa M, Yamakawa K, Okumura S, Nishida S: Antimicrobial susceptibility of Clostridium difficile from different sources. Microbiol Immunol 1982, 26(1):25-30.
• [26]Gianfrilli P, Luzzi I, Pantosti A, Occhionero M: In vitro susceptibility of Clostridium difficile isolates to 12 antimicrobial agents. Chemioterapia 1984, 3(1):41-44.
• [27]Hsu MS, Wang JT, Huang WK, Liu YC, Chang SC: Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan. J Microbiol Immunol Infect 2006, 39(3):242-248.
• [28]Manian FA, Bryant A: Does Candida species overgrowth protect against Clostridium difficile infection? Clin Infect Dis 2013, 56(3):464-465.
• [29]Slimings C, Riley TV: Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014, 69(4):881-891.